Shilpa Medicare Limited (SHILPAMED) — Announcement | 7 July 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

India Ratings upgraded Shilpa Medicare's bank loan facilities to IND AA- with a Positive outlook, while Shilpa Pharma's facilities were also upgraded to IND AA- and IND A1+ respectively, reflecting improved creditworthiness and stable outlooks for both entities.

📄 View Original Announcement (PDF)

About Shilpa Medicare Limited (SHILPAMED)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹17,391.14 Cr P/E: 48.2 ROE: 12.5% ROCE: 13.4% Div Yield: 0.07%

View full SHILPAMED stock details →

📡 Get AI alerts when SHILPAMED files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SHILPAMED — Free

📊 More SHILPAMED filings

See all SHILPAMED filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SHILPAMED files new disclosures

Track SHILPAMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SHILPAMED — Free

Free account · 2 AI queries/day